Skip to main
NEO

NeoGenomics (NEO) Stock Forecast & Price Target

NeoGenomics (NEO) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeoGenomics is poised for long-term success with the recent coverage of its PanTracer LBx test by CMS' MolDX, anticipation of new revenue from the test in 2026, and its diverse revenue streams from clinical cancer testing, molecular and NGS testing, and clinical trials and research. However, challenges exist in the regulatory landscape and the integration of acquired businesses, and there are risks associated with government reimbursement and competitive factors. With strong financial performance in 1Q, the company plans to continue expanding its market share in areas such as liquid biopsy, minimal residual disease testing, and flow cytometry for heme malignancies.

Bears say

NeoGenomics is seeing positive growth in their oncology diagnostic testing and consultative services, but is facing challenges with below-average margins and potential competition from new proprietary technologies in the diagnostics industry. Their recent revenue growth target increase and plans to introduce new indications for MRD testing in the second half of 2026 may drive future multiple expansion, but concerns about profitability and competition could limit potential gains. The company's Q2 revenue guidance, with expected NGS growth and positive FCF in 2026, could offset lower margins and launch costs, but it remains to be seen if they can fully capitalize on their growth potential.

NeoGenomics (NEO) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeoGenomics (NEO) Forecast

Analysts have given NeoGenomics (NEO) a Buy based on their latest research and market trends.

According to 6 analysts, NeoGenomics (NEO) has a Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeoGenomics (NEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.